Rapport Therapeutics (NASDAQ:RAPP) Shares Down 5.7% – Here’s What Happened

Rapport Therapeutics (NASDAQ:RAPP)’s share price was down 5.7% during mid-day trading on Thursday . The company traded as low as $19.10 and last traded at $19.10. Approximately 3,520 shares were traded during trading, a decline of 98% from the average daily volume of 153,359 shares. The stock had previously closed at $20.25.

Rapport Therapeutics Price Performance

The firm’s fifty day simple moving average is $23.18.

Institutional Trading of Rapport Therapeutics

Hedge funds have recently bought and sold shares of the company. Millennium Management LLC acquired a new stake in shares of Rapport Therapeutics during the second quarter valued at approximately $2,716,000. Perceptive Advisors LLC acquired a new stake in Rapport Therapeutics during the 2nd quarter valued at $17,403,000. ARCH Venture Management LLC purchased a new stake in shares of Rapport Therapeutics in the second quarter valued at $86,730,000. TD Asset Management Inc acquired a new stake in shares of Rapport Therapeutics in the second quarter worth $2,361,000. Finally, Johnson & Johnson purchased a new position in shares of Rapport Therapeutics during the second quarter valued at $58,105,000.

Rapport Therapeutics Company Profile

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.